🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

9 recruiting trials

for Moderate to Severe Dry Eye

A Study of the Efficacy and Safety of Cyclosporin Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease NCT06766357Phase 31 site📍 Xiamen Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. · Tests: Cyclosporine ophthalmic gel, Cyclosporine ophthalmic gel vehicle Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) vs Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe DED NCT07412860NA2 sites📍 Cagliari📍 Catanzaro FB Vision S.p.A · Tests: FBV_01, HYLO-VISION® SafeDrop® Gel Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease NCT06964269Phase 41 site📍 Nashville Toyos Clinic · Tests: Acthar Gel 80 UNT/ML Injectable Solution Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye NCT07413172Phase 21 site📍 Miami University of Miami · Tests: Autologous Serum Tears (50% Autologous Serum Tears + 0.2% Sodium Hyaluronate), Biological - Autologous Serum Tears (50%… A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease NCT07041099Phase 114 sites📍 Orlando📍 Brooklyn📍 Memphis Cullinan Therapeutics Inc. · Tests: CLN-978 Phase III Study of OT202 in Treating Moderate to Severe Dry Eye NCT07740564Phase 349 sites📍 Bengbu📍 Hefei📍 Beijing Ocumension Therapeutics (Suzhou) Co., Ltd · Tests: OT202 conc 1%, Placebo 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis NCT06903884Phase 31 site📍 Hong Kong The University of Hong Kong · Tests: 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion, 0.1% Cyclosporin A cationic opht… MTS109 in Patients With Refractory Autoimmune Diseases NCT07526350EARLY Phase 11 site📍 Shanghai Shanghai Changzheng Hospital · Tests: MTS109 A Study to Evaluate the Performance and Safety of Artelac® Complete MDO® Versus VISMED® MULTI Eye Drops in the Management of Moderate to Severe Dry Eye Disease NCT07593885NA12 sites📍 Freiburg im Breisgau📍 Heidelberg📍 Tübingen Dr. Gerhard Mann chem.-pharm. Fabrik GmbH · Tests: Artelac® Complete MDO® Eye Drops, VISMED® MULTI Eye Drops
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy